Search clinical trials for: Oral methylnaltrexone

Total 8224 results

Bausch Health Americas, Inc.

Completed

Tolerance and Pharmacokinetics Study of MNTX Tablets

Normal Healthy Volunteers

United States
University of Missouri-Columbia

Completed

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Constipation Drug Induced

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Healthy Subjects

United States
Bausch Health Americas, Inc.

Completed

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

Healthy Volunteers

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

Liver Dysfunction

United States
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 302

Terminal Illness

United States
Bausch Health Americas, Inc.

Completed

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

Healthy Male Volunteers

United States
Bausch Health Americas, Inc.

Completed

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

Healthy Adults

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Renal Impairment

United States
University Medicine Greifswald

Completed

Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects (LOP-MNTX-2009)

Intestinal Obstruction

Germany
Bausch Health Americas, Inc.
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

Advance Illness Patients With OIC

United States
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 301

Terminal Illness

United States
Bausch Health Americas, Inc.

Completed

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Post Operative Bowel Dysfunction

Germany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
Asbjørn Mohr Drewes
Odense University Hospital; Hvidovre University Hospital; University Hospital...

Completed

Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

Acute Pancreatitis

Denmark
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Portugal, United Kingdom
Region Örebro County
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Opioids and Esophageal Function

Pharyngeal Dysfunction | Esophageal Dysfunction

Sweden
Bausch Health Americas, Inc.

Withdrawn

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Beth Israel Medical Center
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?

Colonic Inertia
Amsterdam UMC, location VUmc
Stichting Nuts Ohra

Terminated

Methylnaltrexone for Opioid Induced Constipation (RILAX)

Constipation

Netherlands
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Withdrawn

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Opioid-Induced Constipation

Canada, United States, France, Spain
Bausch Health Americas, Inc.

Completed

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

Postoperative Ileus

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.

Completed

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Healthy Males

United States
Bausch Health Americas, Inc.
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Opioid-induced Constipation

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Methylnaltrexone in Opioid-Induced Constipation Patients

Opioid-induced Constipation

China
Bausch Health Americas, Inc.

Completed

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.
Pfizer

Completed

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

Constipation

Canada, United States, Colombia, Korea, Republic of, Australia, Spain
Mayo Clinic
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

Gastric Motility Disorder

United States
Bausch Health Americas, Inc.

Withdrawn

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Pancreatic Cancer
Bausch Health Americas, Inc.
Pfizer

Completed

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Advanced Illness Patients With Opioid Induced Constipation

United States
University of Vermont

Completed

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

Neoplasms | Constipation | Opioid-Related Disorders

United States
University of Alabama at Birmingham

Recruiting

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Chronic Widespread Pain

United States
Bausch Health Americas, Inc.

Completed

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Healthy Adults

United States
Karolinska University Hospital

Completed

Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients (MOVEMENT)

STEMI | Morphine | Ticagrelor | Methylnaltrexone

Sweden
St. John Health System, Michigan

Unknown

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit (MOVE-IT)

Opioid-induced Constipation

United States
Encysive Pharmaceuticals

Completed

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States
Universitaire Ziekenhuizen KU Leuven

Completed

The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

Endogenous and Esophageal Sensitivity
Bausch Health Americas, Inc.

Completed

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Healthy Volunteers

United States
Bausch Health Americas, Inc.

Completed

Compassionate Use Study of Methylnaltrexone

Opioid-induced Constipation

United States
Tufts Medical Center

Terminated

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Constipation

United States
Eunice Kennedy Shriver National Institute of Child...

Terminated

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

Amenorrhea | Aplastic Anemia | Menorrhagia

United States
Ohio State University

Completed

Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention

Postoperative Ileus

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Constipation

Korea, Republic of, Taiwan
Bausch Health Americas, Inc.

Completed

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Bowel Dysfunction

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Ileus

United States, South Africa, Canada, Hungary, Poland, Australia, Belgium, Germany, Italy, Korea, Republic of, Netherlands
M.D. Anderson Cancer Center

Recruiting

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Head and Neck Squamous Cell Carcinoma

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Opioid-Induced Constipation

United States
University of Zurich

Completed

Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients (RELZH12)

Opioid Use, Unspecified With Other Opioid-induced Disorder

Switzerland

Search clinical trials for: Oral methylnaltrexone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations